NR4A Nuclear Receptor Function in Leukemia
NR4A 核受体在白血病中的功能
基本信息
- 批准号:7936495
- 负责人:
- 金额:$ 2.55万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-01-18 至 2010-12-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAcute Myelocytic LeukemiaAge-MonthsAllelesApoptosisApoptoticAutomobile DrivingBirthBlast PhaseCell CycleCell ProliferationCell SurvivalCellsChronicChronic Myeloid LeukemiaChronic Myeloproliferative DisorderChronic-Phase Myeloid LeukemiaCommitCommunicationComplexDNADataDevelopmentDisease ProgressionElementsEquilibriumGene DosageGene TargetingGenesGenetic ProgrammingHematopoieticHematopoietic stem cellsHumanImmediate-Early GenesKnockout MiceLigandsModelingMolecular GeneticsMusMutant Strains MiceMyelogenousMyeloid CellsMyeloid LeukemiaMyeloid Progenitor CellsMyelopoiesisMyeloproliferative diseaseNuclear ReceptorsOncogenesOncogenicOrphanPhasePhenotypePhysiologicalPlayProtein Sequence HomologsProteinsRegulationResearch PersonnelRoleSignal PathwaySignal TransductionStimulusSystemTestingTissuesTransgenic OrganismsTumor Suppressor Proteinsactivating transcription factorbasebcr-abl Fusion Proteinscellular targetingextracellularinsightleukemiamembermouse modelnovelpreventprogenitorprogramsprotein expressionreceptorreceptor functionresponseself-renewalstemtranscription factor
项目摘要
The overall objective of this project is to elucidate the mechanisms by which the nuclear receptors nor-1 and
nur77 function as tumor suppressors to prevent the development of myeloid leukemia. Nur77 and nor-1 are
members of the NR4A subfamily of nuclear receptor transcription factors. NR4A receptors have highly
homologous amino acid sequences and can interact with common cis-acting DNA elements to regulate
overlapping target genes. Unlike most nuclear receptors, NR4A subfamily members are not ligand activated
and can function as constitutively active transcription factors. In addition, they are products of immediate
early genes whose expression and activity are regulated in a cell specific manner in response to a variety of
extracellular mitogenic, apoptotic and differentiative stimuli. In order to elucidate the essential physiological
roles of NR4A receptors, we have generated null mutant mice in which the expression of these proteins has
been ablated. The current proposal is based on our recent discovery that mice deficient in both nur77 and
nor-1 develop rapidly lethal myeloid leukemia that is nor1/nur77 gene dosage dependent in its latency of
development and most closely resembles the acute phase of chronic myeloid leukemia (CML). We
hypothesize that norl and nur77 are essential tumor suppressor transcription factors operating most likely in
hematopoietic stem (HSCs) or downstream myeloid progenitor cells and exert their effects by communication
with cell cycle components to regulate the balance between serf renewal, proliferation and cell survival. We
further hypothesize that inactivation of nor1/nur77 may play a key role in driving progression of chronic
myeloproliferative disease to acute phase. To test this hypothesis, we will 1) continue to examine the cellular
mechanisms of initiation and progression of myeloid leukemia in nor1/nur77 null mutant mice, 2) identify the
nor1/nur77 dependent molecular genetic signaling pathways that control myelopoietic cell development, 3)
determine whether loss of nor1/nur77 cooperates with BCR-ABL oncogenic signaling to drive acute phase
progession in a mouse model of CML, and 4) determine whether transgenic targeting of norl and nur77 to
myeloid progenitor cells is sufficient to rescue the leukemic phenotype in nor1/nur77 null mice.
本项目的总体目标是阐明核受体nor-1和
NUR 77作为肿瘤抑制剂起作用以防止髓性白血病的发展。Nur-77和Nor-1是
核受体转录因子NR 4A亚家族成员。NR 4A受体具有高度的
同源氨基酸序列,并可与常见的顺式作用DNA元件相互作用,以调节
重叠靶基因。与大多数核受体不同,NR 4A亚家族成员不是配体激活的
并且可以作为组成型活性转录因子发挥作用。此外,它们是直接
早期基因,其表达和活性以细胞特异性方式响应于多种
细胞外促有丝分裂、凋亡和分化刺激。为了阐明基本的生理
NR 4A受体的作用,我们已经产生了无效突变小鼠,其中这些蛋白质的表达具有
被消融了。目前的建议是基于我们最近的发现,即nur 77和
nor-1发展为快速致死性髓系白血病,其潜伏期依赖于nor 1/nur 77基因剂量。
慢性粒细胞性白血病(CML)是一种慢性粒细胞性白血病(CML)。我们
假设norl和nur 77是最有可能在
造血干细胞(HSC)或下游骨髓祖细胞,并通过通讯发挥其作用
与细胞周期组分一起调节自我更新、增殖和细胞存活之间的平衡。我们
进一步假设nor 1/nur 77的失活可能在驱动慢性炎症进展中起关键作用,
骨髓增生性疾病急性期。为了验证这一假设,我们将1)继续检查细胞
在nor 1/nur 77无效突变小鼠中髓性白血病的起始和进展机制,2)鉴定
nor 1/nur 77依赖的控制骨髓细胞发育的分子遗传信号通路,3)
确定nor 1/nur 77的缺失是否与BCR-ABL致癌信号传导协同作用以驱动急性期
4)确定norl和nur 77在CML小鼠模型中的转基因靶向作用是否与CML小鼠模型中的表达相关,以及
髓样祖细胞足以挽救NOR 1/Nur 77缺失小鼠中的白血病表型。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ORLA M. CONNEELY其他文献
ORLA M. CONNEELY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ORLA M. CONNEELY', 18)}}的其他基金
DISCOVERY OF SMALL MOLECULAR ACTIVATORS OF NR4A ORPHAN NUCLEAR RECEPTORS
NR4A 孤儿核受体小分子激活剂的发现
- 批准号:
8292458 - 财政年份:2012
- 资助金额:
$ 2.55万 - 项目类别:
DISCOVERY OF SMALL MOLECULAR ACTIVATORS OF NR4A ORPHAN NUCLEAR RECEPTORS
NR4A 孤儿核受体小分子激活剂的发现
- 批准号:
8542797 - 财政年份:2012
- 资助金额:
$ 2.55万 - 项目类别:
DISCOVERY OF SMALL MOLECULAR ACTIVATORS OF NR4A ORPHAN NUCLEAR RECEPTORS
NR4A 孤儿核受体小分子激活剂的发现
- 批准号:
8891381 - 财政年份:2012
- 资助金额:
$ 2.55万 - 项目类别:
DISCOVERY OF SMALL MOLECULAR ACTIVATORS OF NR4A ORPHAN NUCLEAR RECEPTORS
NR4A 孤儿核受体小分子激活剂的发现
- 批准号:
8678873 - 财政年份:2012
- 资助金额:
$ 2.55万 - 项目类别:
DISCOVERY OF SMALL MOLECULAR ACTIVATORS OF NR4A ORPHAN NUCLEAR RECEPTORS
NR4A 孤儿核受体小分子激活剂的发现
- 批准号:
9081541 - 财政年份:2012
- 资助金额:
$ 2.55万 - 项目类别:
Nuclear Receptor, Transcription and Chromatin Biology Program
核受体、转录和染色质生物学项目
- 批准号:
10239128 - 财政年份:2007
- 资助金额:
$ 2.55万 - 项目类别:
Nuclear Receptor, Transcription and Chromatin Biology Program
核受体、转录和染色质生物学项目
- 批准号:
10025018 - 财政年份:2007
- 资助金额:
$ 2.55万 - 项目类别:
相似海外基金
Computing analysis of leukemic stem cell dynamics in acute myelocytic leukemia
急性粒细胞白血病白血病干细胞动力学的计算分析
- 批准号:
19K08356 - 财政年份:2019
- 资助金额:
$ 2.55万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Generation of immunotoxins with super-targeting mAb in the acute myelocytic leukemia
在急性髓细胞白血病中使用超靶向单克隆抗体产生免疫毒素
- 批准号:
23501309 - 财政年份:2011
- 资助金额:
$ 2.55万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
DETERMINANTS OF RESPONSE OF ACUTE MYELOCYTIC LEUKEMIA
急性粒细胞白血病反应的决定因素
- 批准号:
3556971 - 财政年份:1980
- 资助金额:
$ 2.55万 - 项目类别:
DETERMINANTS OF RESPONSE OF ACUTE MYELOCYTIC LEUKEMIA
急性粒细胞白血病反应的决定因素
- 批准号:
3556968 - 财政年份:1980
- 资助金额:
$ 2.55万 - 项目类别:
ERADICATION OF ACUTE MYELOCYTIC LEUKEMIA CELLS BY MAB THERAPY
通过 MAB 疗法根除急性粒细胞白血病细胞
- 批准号:
3889304 - 财政年份:
- 资助金额:
$ 2.55万 - 项目类别: